Picard Medical announced that the NYSE American has accepted its plan to regain compliance with continued listing standards. The acceptance allows the company to keep its common stock listed and trading under ticker symbol PMI while it executes operational, strategic, and financial initiatives. Picard Medical has been granted a compliance period through November 8, 2027, subject to periodic review. The company is the parent of SynCardia Systems, maker of the only FDA-approved total artificial heart.
Picard Medical, Inc.NYSE American accepted compliance plan, allowing continued listing